Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mechanistic models for myelosuppression.

Lena E Friberg1, Mats O Karlsson

  • 1Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden. Lena.Friberg@farmbio.uu.se

Investigational New Drugs
|August 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same author

Evaluating neoantigen-vaccine responses through mechanistic and model-based frameworks.

NPJ precision oncology·2026
Same author

A glimpse into the future of model-informed drug discovery and development.

Advanced drug delivery reviews·2026
Same author

Evaluation of sNfL as a Biomarker for Paclitaxel-Induced Peripheral Neurotoxicity Through an Integrated PKPD Model.

Pharmaceutical research·2026
Same author

Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.

Antimicrobial agents and chemotherapy·2026
Same author

Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing <i>in vivo</i>.

Antimicrobial agents and chemotherapy·2026
Same journal

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

Investigational new drugs·2026
Same journal

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026
Same journal

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

Investigational new drugs·2026
Same journal

Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

Investigational new drugs·2026
Same journal

Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

Investigational new drugs·2026
Same journal

Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

Investigational new drugs·2026
See all related articles

Mechanistic pharmacokinetic-pharmacodynamic models are crucial for optimizing chemotherapy by predicting myelosuppression. These models use the full drug concentration-time profile to forecast toxicity, aiding clinical trial design and patient risk stratification.

Area of Science:

  • Pharmacology and Toxicology
  • Mathematical Modeling
  • Clinical Trial Design

Background:

  • Myelosuppression is a dose-limiting toxicity in chemotherapy.
  • Mechanistic pharmacokinetic-pharmacodynamic (PK-PD) models are preferred over empirical models for their reliability and ability to incorporate prior knowledge.
  • Modeling the entire concentration-time profile and myelosuppression time course is essential for accurate predictions.

Purpose of the Study:

  • To review existing semi-mechanistic PK-PD models for myelosuppression.
  • To highlight the importance of using the whole concentration-time profile and modeling the full time course of toxicity.
  • To emphasize the need for models that separate drug-specific and system-related parameters for broader applicability.

Main Methods:

Related Experiment Videos

  • Review of published semi-mechanistic PK-PD models for myelosuppression.
  • Analysis of model properties, including input requirements (concentration-time profile) and output (toxicity time course).
  • Discussion of ideal model characteristics for clinical application.

    • Main Results:

    • Several semi-mechanistic PK-PD models with the desired properties have been developed.
    • These models enable prediction of toxicity degree, duration, and impact on subsequent treatment courses.
    • Separating drug-specific from system parameters enhances model generalizability.

    Conclusions:

    • Mechanistic PK-PD models are vital for optimizing chemotherapy regimens and managing myelosuppression.
    • Implementing these models in clinical trials can optimize sampling times, doses, and regimens.
    • These models can identify patient subgroups at high risk for myelosuppression, improving personalized medicine.